<DOC>
	<DOCNO>NCT00902174</DOCNO>
	<brief_summary>A multinational , multicenter , double blind , placebo-controlled study evaluate efficacy safety imatinib add-on therapy treatment patient severe pulmonary arterial hypertension ( PAH ) .</brief_summary>
	<brief_title>Imatinib ( QTI571 ) Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Key Inclusion criterion Male female patient ≥18 year age current diagnosis pulmonary arterial hypertension ( PAH ) accord Dana Point 2008 Meeting : World Health Organization ( WHO ) Diagnostic Group I , idiopathic heritable ( familial sporadic ) PAH , PAH associate collagen vascular disease include systemic sclerosis , rheumatoid arthritis , mixed connective tissue disease , overlap syndrome . PAH follow one year repair congenital heart defect [ Atrial Septal Defect ( ASD ) , Ventricular Septal Defect ( VSD ) Posterior Descending Artery ( PDA ) ] , PAH associate diet therapy drug A Pulmonary Vascular Resistance ( PVR ) ≥ 800 dynes.sec.cm5 ( assess Right Heart Catheterization ( RHC ) screen 3 month precede screen visit ) despite treatment two specific PAH therapy , include Endothelin Receptor Antagonists ( ERAs ) , phosphodiesterase 5 inhibitor ( PDE5 ) , subcutaneous , inhaled , intravenous oral prostacyclin analogue ≥ 3 month . Background therapy dose stable ≥ 30 day except warfarin prostacyclin analogue ( ≥ 30 day dos could vary even within month enrollment ) . World Health Organization functional Class IIIV . For WHO Functional Class IV , one 2 specific PAH therapy inhale , subcutaneous , intravenous oral prostacyclin analogue , unless subject show intolerance prostacyclin analogue . 6MWD ≥ 150 meter ≤ 450 meter screen . Distances two consecutive 6MWTs within 15 % one another . Key Exclusion criterion With pulmonary capillary wedge pressure &gt; 15 mm Hg rule PAH secondary leave ventricular dysfunction . With diagnosis pulmonary artery vein stenosis Left ventricular ejection fraction ( LVEF ) &lt; 45 % With Disseminated Intravascular Coagulation ( DIC ) With evidence major bleed intracranial hemorrhage With history elevate intracranial pressure With history latent bleed risk diabetic retinopathy , gastrointestinal bleeding due gastric duodenal ulcer , colitis ulcerosa With QTcF &gt; 450 msec male &gt; 470 msec female screen baseline absence right bundle branch block . With history ventricular tachycardia , ventricular fibrillation ventricular flutter With history Torsades de Pointes With history long QT syndrome Having undergone atrial septostomy 3 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Imatinib</keyword>
	<keyword>6MWD</keyword>
	<keyword>Borg scale</keyword>
	<keyword>Pulmonary hypertension</keyword>
</DOC>